TROVAGENE INC. overview

LOS ANGELES, CA / ACCESSWIRE / July 26, 2017 / StockNewsNow.com , The Official MicroCap News Source™, today published SNNLive Video Interview with Bill Welch, CEO of Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, according to the company's website (see here: https://www.trovagene.com ). The video interview was recorded on Wednesday, June 7 th , 2017 at the LD Micro Invitational 2017 in Bel Air, CA. Click the following link to watch the SNNLive Video Interview on...

Trovagene Announces Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia PR Newswire SAN DIEGO, June 26, 2017 SAN DIEGO , June 26, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. Patent and Trademark Office, and separately, the European Patent Office, have allowed claims for Patent Application 13/959739 and Patent Application EP10184598.0, respectively, entitled "Nucleophosmin Protein (NPM)...

Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera® ctDNA Tests and Services in Cancer Clinical Trials PR Newswire SAN DIEGO, June 22, 2017 SAN DIEGO , June 22, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced it has entered into an agreement with a worldwide, premier biopharmaceutical company to provide Trovera® urine circulating tumor DNA (ctDNA) biomarker tests and services. The Trovera®...

Trovagene Enters Into Agreement with AstraZeneca to Utilize Trovera® ctDNA Test and Services in Prospective Biomarker Study PR Newswire SAN DIEGO, June 12, 2017 SAN DIEGO , June 12, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company today announced it has entered into an agreement with AstraZeneca to provide Trovera® urine ctDNA biomarker test and services. The Trovera® EGFR urine liquid biopsy test will initially be used in an open label...

Trovagene to Present at the Marcum 2017 MicroCap Conference on June 15 in New York City PR Newswire SAN DIEGO, June 1, 2017 SAN DIEGO , June 1, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch , will be presenting at the Marcum 2017 MicroCap Conference on June 15, 2017 at 3:00 PM EDT at the Grand Hyatt Hotel in Julliard on the conference level. Management will also be available to meet...

Trovagene to Present at the 7th Annual LD Micro Invitational Conference on June 7, 2017 in Los Angeles PR Newswire SAN DIEGO, May 23, 2017 SAN DIEGO , May 23, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch , will be presenting at the 7th Annual LD Micro Invitational Conference June 7, 2017 at 11:30 AM PDT at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Management will also be...

Trovagene Announces First Quarter 2017 Company Highlights and Financial Results PR Newswire SAN DIEGO, May 10, 2017 SAN DIEGO , May 10, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced company highlights and financial results for the first quarter ended March 31 , 2017. "We are excited about the advancement of our business in precision medicine and the development of precision cancer therapeutics for improved cancer care. This...

Trovagene to Announce First Quarter 2017 Financial Results and Host Conference Call on Wednesday, May 10, 2017 PR Newswire SAN DIEGO, April 26, 2017 SAN DIEGO , April 26, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, announced today that it will report financial results for the first quarter ended March 31, 2017 on Wednesday, May 10, 2017 . Trovagene's senior management team will host a conference call on Wednesday, May 10, 2017 at 5:00 p.m....